1
|
Kamilova U, Ermekbaeva A, Nuritdinov N, Khamraev A, Zakirova G. Occurrence of comorbid diseases in patients after COVID-19. J Med Life 2023; 16:447-450. [PMID: 37168295 PMCID: PMC10165508 DOI: 10.25122/jml-2022-0168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 12/07/2022] [Indexed: 05/13/2023] Open
Abstract
The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes.
Collapse
Affiliation(s)
- Umida Kamilova
- Department of Therapy, Tashkent Medical Academy, Tashkent, Uzbekistan
- Corresponding Author: Umida Kamilova, Department of Therapy, Tashkent Medical Academy, Tashkent, Uzbekistan. E-mail:
| | - Akbal Ermekbaeva
- Department of Therapy, Tashkent Medical Academy, Tashkent, Uzbekistan
| | - Nuriddin Nuritdinov
- Department of Cardiology, Republican Specialized Scientific and Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, Uzbekistan
| | - Abror Khamraev
- Department of Therapy, Tashkent Medical Academy, Tashkent, Uzbekistan
| | | |
Collapse
|
2
|
Tsaryk I, Pashkovska N. The role of renal damage markers in the diagnosis of early stages of kidney injury in patients with latent autoimmune diabetes in adults. J Med Life 2022; 15:792-796. [PMID: 35928354 PMCID: PMC9321499 DOI: 10.25122/jml-2022-0062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 05/10/2022] [Indexed: 11/13/2022] Open
Abstract
Serum creatinine level begins to increase after a decrease in glomerular filtration rate (GFR) by 50% and more, so the question emerged about a more accurate method of determining GFR. The study aimed to determine the role of renal damage markers in the diagnosis of early-stage renal disease in patients with latent autoimmune diabetes in adults (LADA). We included 84 patients with diabetes mellitus (DM) and chronic kidney disease (CKD) caused by diabetic kidney disease (DKD), as well as 25 representatives of the control group. Patients were divided into three groups - 43 people with LADA, 21 with type 1 diabetes mellitus (T1DM), and 20 patients with type 2 diabetes mellitus (T2DM). GFR was assessed using six formulas after establishing the category of GFR and albuminuria. The GFR rate estimated by the CKD-EPI formula in patients with LADA and DKD did not significantly differ from that of CKD-EPI cysC, slightly different from MDRD GFR (10.6% higher, respectively) but 21.9% lower compared to CG formula. In patients with LADA and T1DM, GFR was higher in cases with existing albuminuria, regardless of the formulas used. Thus, the non albuminuria phenotype is accompanied by a greater degree of renal impairment, which indicates the need to determine serum cystatin C in the early stages of LADA. Cystatin C levels are the most accurate, early, and independent predictor of the development and progression of CKD in patients with DM, including LADA.
Collapse
Affiliation(s)
- Iryna Tsaryk
- Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Chernivtsi, Ukraine,Corresponding Author: Iryna Tsaryk, Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Chernivtsi, Ukraine. E-mail:
| | - Nataliia Pashkovska
- Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Chernivtsi, Ukraine
| |
Collapse
|
3
|
Avram RL, Nechita AC, Popescu MN, Teodorescu M, Ghilencea LN, Turcu D, Lechea E, Maher S, Bejan GC, Berteanu M. Functional tests in patients with ischemic heart disease. J Med Life 2022; 15:58-64. [PMID: 35186137 PMCID: PMC8852644 DOI: 10.25122/jml-2019-0142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Accepted: 04/18/2020] [Indexed: 11/19/2022] Open
Abstract
Lately, easier and shorter tests have been used in the functional evaluation of cardiac patients. Among these, walking speed (WS) and Timed Up and Go (TUG) tests are associated with all-cause mortality, mainly cardiovascular and the rate of re-hospitalization, especially in the elderly population. We prospectively analyzed a group of 38 patients admitted to the Cardiology Clinic from Elias Hospital, Romania, with chronic coronary syndrome (CCS) (n=22) and STEMI (n=16). We assessed the patients immediately after admission and before discharge with G-WALK between the 1st and 30th of September 2019. Our study group had a mean age of 62.7±12.1 years. Patients with a low WS were older (69.90±12.84 vs. 59.90±10.32 years, p=0.02) and had a lower serum hemoglobin (12.38±1.20 vs. 13.72±2.07 g/dl, p=0.02). The WS significantly improved during hospitalization (p=0.03) after optimal treatment. The TUG test performed at the time of admission had a longer duration in patients with heart failure (14.05 vs. 10.80 sec, p=0.02) and was influenced by patients' age (r=0.567, p=0.02), serum creatinine (r=0.409, p=0.03) and dilation of right heart chambers (r=0.399, p=0.03). WS and TUG tests can be used in patients with CCS and STEMI, and are mainly influenced by age, thus having a greater value among the elderly.
Collapse
Affiliation(s)
- Rodica Lucia Avram
- Cardiology Department, Sf. Pantelimon Emergency Hospital, Bucharest, Romania,Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania
| | - Alexandru Cristian Nechita
- Cardiology Department, Sf. Pantelimon Emergency Hospital, Bucharest, Romania,Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania
| | - Marius Nicolae Popescu
- Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania,Rehabilitation Department, Elias Emergency Hospital, Bucharest, Romania
| | - Matei Teodorescu
- Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania,Rehabilitation Department, Elias Emergency Hospital, Bucharest, Romania
| | - Liviu-Nicolae Ghilencea
- Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania,Cardiology Department, Elias Emergency Hospital, Bucharest, Romania,Corresponding Author: Liviu-Nicolae Ghilencea, Cardiology Department, Elias Emergency Hospital, Bucharest, Romania. E-mail:
| | - Diana Turcu
- Cardiology Department, Elias Emergency Hospital, Bucharest, Romania
| | - Elena Lechea
- Cardiology Department, Elias Emergency Hospital, Bucharest, Romania
| | - Sean Maher
- Surgery Department, St. Vincent’s University Hospital, Dublin, Ireland
| | - Gabriel Cristian Bejan
- Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania,Private Medical Practice Office Bejan Gabriel Cristian, Bucharest, Romania
| | - Mihai Berteanu
- Internal Medicine Department, Carol Davila Medicine and Pharmacy University, Bucharest, Romania,Rehabilitation Department, Elias Emergency Hospital, Bucharest, Romania
| |
Collapse
|
4
|
Coppolino G, Comi N, Bolignano D, Patella G, Comi A, Provenzano M, Rivoli L, Andreucci M, Fuiano G. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Renal Function Decline in Patients With Glomerular Diseases. Front Cell Dev Biol 2020; 8:336. [PMID: 32548113 PMCID: PMC7272710 DOI: 10.3389/fcell.2020.00336] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 04/17/2020] [Indexed: 12/18/2022] Open
Abstract
Objective Available biomarkers for monitoring primary glomerulonephritides (GNs), often lack the ability to assess longitudinal changes and have great variability with poor sensitivity. Accruing evidence has demonstrated that Neutrophil Gelatinase-Associated Lipocalin (NGAL), holds promising capacities in predicting renal function worsening in various renal diseases. We aimed at analyzing urinary NGAL (uNGAL) levels in a cohort of individuals with biopsy-proven GNs in order to evaluate its ability to reflect the entity of renal damage and to predict disease evolution overtime. Methods We enrolled 61 consecutive GNs patients still naïve to pathogenic therapy. uNGAL levels were measured at baseline and patients prospectively followed until the manifestation of a combined outcome of doubling of baseline serum creatinine and/or end-stage kidney disease requiring permanent dialysis support. Results Median uNGAL levels were 107[35–312] ng/mL. At univariate and multivariate analyses an inverse correlation was found between eGFR and uNGAL levels (p = 0.001). Progressor subjects showed exceedingly increased baseline uNGAL values as compared with non-progressors (p < 0.001). Twenty-one patients (34%) reached the composite renal endpoint. Subjects with uNGAL values above the optimal, ROC-derived, cut-off of 107 ng/mL experienced a more rapid progression to the renal endpoint (p < 0.001; HR: 5.47; 95% CI 2.31–12.95) with a mean follow-up time to progression of 73.4 vs 83.5 months. Conclusion In patients affected by primary glomerulonephritides, uNGAL may represent a real-time indicator of renal damage and an independent predictor of renal disease progression. Further studies on larger populations are warranted to confirm these findings.
Collapse
Affiliation(s)
| | - Nicola Comi
- Renal Unit, "Magna Graecia" University, Catanzaro, Italy
| | | | - Gemma Patella
- Renal Unit, "Magna Graecia" University, Catanzaro, Italy
| | | | | | - Laura Rivoli
- Renal Unit, "Magna Graecia" University, Catanzaro, Italy
| | | | - Giorgio Fuiano
- Renal Unit, "Magna Graecia" University, Catanzaro, Italy
| |
Collapse
|